Rabeprazole Sodium
12 NDCs across 6 manufacturers|12 Generic,0 Brand
Rabeprazole Sodium is used to treat duodenal ulcer, gastroesophageal reflux, heartburn, helicobacter infections and zollinger-ellison syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Aug 19, 1999, and the first generic was approved Nov 8, 2013. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $30 million on Rabeprazole Sodium across 289,000 claims for 81,000 beneficiaries.
Rabeprazole Sodium is available as 12 NDCs from 6 manufacturers (12 generic, 0 brand), with NADAC prices from $0.22 to $0.25 per EA — a 12% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
12
12G / 0B
Manufacturers
6
competing in market
Price Spread
$0.22 – $0.25
per EA
7d Activity
avg +7.0% WoW · of 12 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Lannett Company Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Proton Pump Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing RABEPRAZOLE SODIUM(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RABEPRAZOLE SOD DR 20 MG TAB | $0.2507 per EA | — |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
RABEPRAZOLE SOD DR 20 MG TAB | $0.2238 per EA | +6.95% |
Frequently Asked Questions
What is Rabeprazole Sodium used to treat?
Rabeprazole Sodium is used to treat duodenal ulcer, gastroesophageal reflux, heartburn, helicobacter infections and zollinger-ellison syndrome, per the National Library of Medicine's MED-RT classification.
When did Rabeprazole Sodium become available as a generic?
FDA approved the first generic Rabeprazole Sodium (ANDA) on Nov 8, 2013. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rabeprazole Sodium?
In 2024, Medicare Part D spent $30 million on Rabeprazole Sodium across 289,000 claims for 81,000 beneficiaries.
How many Rabeprazole Sodium products are on the market?
The Rabeprazole Sodium drug market contains 12 NDCs from 6 manufacturers — 12 generic and 0 brand products.
What is the price range for Rabeprazole Sodium?
NADAC reference prices for Rabeprazole Sodium range from $0.2238 to $0.2507 per EA — a 12% difference between cheapest and most expensive.
Which manufacturers make Rabeprazole Sodium?
6 manufacturers list Rabeprazole Sodium in NADAC. Ranked by number of NDCs, the largest are Lannett Company Inc. (3), Torrent Pharmaceuticals Limited (2), Aurobindo Pharma Limited (2), Ascend Laboratories, LLC (2), Advagen Pharma Ltd. (2).
How has the price of Rabeprazole Sodium changed recently?
Over the past 7 days, 11 Rabeprazole Sodium NDCs rose and 0 fell, with a market-wide average change of +7.0%.